High Numbers of Differentiated Effector CD4 T Cells Are Found in Patients with Cancer and Correlate with Clinical Response after Neoadjuvant Therapy of Breast Cancer

Péguillet, Isabelle; Milder, Maud; Louis, Delphine; Vincent‐Salomon, Anne; Piperno‐Neumann, Sophie; Scholl, Suzy; Lantz, Olivier

doi:10.1158/0008-5472.can-13-2269

Cited by 34 publications

(30 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…T cells) are reportedly correlated with better prognosis in breast cancer patients [17,[22][23][24]. Some reports attempted to present TILs as a predictive factor of neoadjuvant chemotherapy response in breast cancer [18,19,[25][26][27]. Therefore, TILs both eradicated local tumors and prevented recurrence in breast cancer patients.…”

Section: Discussionmentioning

confidence: 99%

Tumor-infiltrating CD45RO+ memory cells are associated with a favorable prognosis breast cancer

Yajima

Fujii

et al. 2015

Breast Cancer

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Tumor-infiltrating CD45RO+ memory cells are associated with a favorable prognosis breast cancer

Yajima

Fujii

et al. 2015

Breast Cancer

View full text Add to dashboard Cite

show abstract

“…In fact, vaccines against some infectious agents, such as the influenza virus, are more efficacious if administered shortly (5 d) after BC chemotherapy than if they are given 11 d later 68 , proving that such chemotherapeutic regimens are compatible with the induction of an efficient immune response. After neoadjuvant chemotherapy, the number of differentiated CD25 − CD127 − CD4 + T cells increases in the circulation of BC patients, correlating with the degree of tumor regression 69 . Neoadjuvant chemotherapy with taxanes or anthracyclines also increases the frequency of TILs and tumor-infiltrating myeloid cells in subjects with BC 70,71 .…”

mentioning

confidence: 99%

Natural and therapy-induced immunosurveillance in breast cancer

Kroemer

Senovilla

Galluzzi

et al. 2015

Nat Med

265

199

View full text Add to dashboard Cite

The immunosurveillance theory postulates that tumors evolve and progress in an uncontrolled fashion only when anticancer immune responses fail. Natural immunosurveillance clearly influences human breast cancer (BC) progression because the prognosis of BC patients is dictated by the density, composition and activity of the tumor immune infiltrate at diagnosis. Moreover, chemotherapeutic and radiotherapeutic regimens commonly employed for the treatment of BC affect the tumor immune infiltrate, and accumulating data suggest that the clinical efficacy of these treatments is largely determined by T cell-dependent tumor-specific immune responses. In addition, the mechanism of action of targeted anticancer therapeutics, such as the erb-b2 receptor tyrosine kinase 2 (ERBB2)-targeting agent trastuzumab, involves the innate and adaptive arms of the immune system. In this Review, we discuss these findings as well as preliminary evidence indicating that immunotherapy constitutes a promising option for the treatment of BC. Moreover, we point out that the successful implementation of immunotherapy to BC management requires the optimization of current immunotherapeutic regimens and the identification of immunological biomarkers that enable improved risk stratification and the design of personalized, dynamic treatment plans.

show abstract

“…In humans, transfer of autologous-expanded tumor-specific CD4 + T cells induced complete remissions (9,10). We recently evidenced that chronically activated effector CD4 + T cells are increased in the blood of cancer patients, and this expansion is correlated with tumor regression during neoadjuvant chemotherapy of breast cancer (11). Moreover, the presence of a similar CXCL13 secreting CD4 + T cell subset in breast (12) and colon (13) tumors is correlated with a better prognosis.…”

Section: †mentioning

confidence: 99%

Modeling the Specific CD4+ T Cell Response against a Tumor Neoantigen

Flament

Ramírez

Prémel

et al. 2015

The Journal of Immunology

Self Cite

View full text Add to dashboard Cite

The antitumor activity of CD4+ T cells is increasingly acknowledged in both humans and mice. The involved mechanisms have been mostly studied using transplanted tumor mouse systems. In these models, many tumor cells die at the time of implantation leading to the release of Ag in an inflammatory context contrasting with the slow and nondestructive growth of early-stage human tumors. In this study, we show that the presentation of a MHC class II–restricted model Ag (male, DBY) released by dying tumor cells may last more than 4 wk. The duration of Ag presentation varies according to the way the cells are killed before implantation. To avoid this artifactual early priming of the host precluding the study of the interactions between the immune system and tumors at the steady state, we generated a cell line expressing the DBY Ag in an inducible manner. Ag expression can be efficiently induced in vivo several days after tumor implantation. We show that the Ag reaches the lymph node and activates naive CD4+ T cells to proliferate and recirculate. We did not observe de novo induction of tumor-specific regulatory T cells. However, we observed Th1/Th17 effector cells in the tumor draining lymph node and tumors. Thus, when a neoantigen appears in established tumors, the immune system is not ignorant and naive CD4+ T cells are not tolerized. This opens up the possibility of therapeutic vaccines improving the immune response toward tumor-specific neoantigens.

show abstract

High Numbers of Differentiated Effector CD4 T Cells Are Found in Patients with Cancer and Correlate with Clinical Response after Neoadjuvant Therapy of Breast Cancer

Cited by 34 publications

References 50 publications

Tumor-infiltrating CD45RO+ memory cells are associated with a favorable prognosis breast cancer

Tumor-infiltrating CD45RO+ memory cells are associated with a favorable prognosis breast cancer

Natural and therapy-induced immunosurveillance in breast cancer

Modeling the Specific CD4+ T Cell Response against a Tumor Neoantigen

Contact Info

Product

Resources

About